Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum

Pharmacological Research

Volumn 56, Issue 3, 2007, Pages 209-216

  Yousif, Mariam H M ^a   Kehinde, Elijah O ^a   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Aging; Angiotensin; diabetes; Erectile dysfunction; Nitric oxide

Indexed keywords

A 779; ALLOXAN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; CALCIUM ACTIVATED POTASSIUM CHANNEL; CARBACHOL; IBERIOTOXIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETES MELLITUS; DRUG RESPONSE; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

AGING; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; CARBACHOL; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; IMPOTENCE; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; PENIS; PEPTIDE FRAGMENTS; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; PROTO-ONCOGENE PROTEINS; RABBITS; RECEPTORS, G-PROTEIN-COUPLED; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 34548248723     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.05.008     Document Type: Article

References (45)

1. Musicki B., and Burnett A.L. Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res 19 (2007) 129-138
2. Kifor I., Williams G.H., Vickers M.A., Sullivan M.P., Jodbert P., and Dluhy R.G. Tissue angiotensin II as a modulator of erectile function. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 157 (1997) 1920-1925
3. Park K., Shin J.W., Oh J.K., Ryu K.S., Kim S.W., and Paick J. Restoration of erectile capacity in normotensive aged rats by modulation of angiotensin receptor type 1. J Androl 26 (2005) 123-128
4. Ferrario C.M. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47 (2006) 515-521
5. Santos R.A., and Ferreira A.J. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 16 (2007) 122-128
6. Benter I.F., Diz D.I., and Ferrario C.M. Cardiovascular actions of angiotensin-(1-7). Peptides 14 (1993) 679-684
7. Kostenis E., Milligan G., Christopoulos A., Sanchez-Ferrer C.F., Heringer-Walther S., Sexton P.M., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111 (2005) 1806-1813
8. Keidar S., Kaplan M., and Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 73 (2007) 463-469
9. Benter I.F., Diz D.I., Morris M., and Ferrario C.M. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 269 (1995) H313-H319
10. Tallant E.A., and Clark M.A. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42 (2003) 574-579
11. Ferreira A.J., and Santos R.A.S. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 38 (2005) 499-507
12. Ueda S., Masumori-Maemoto S., Ashino K., Nagahara T., Gotoh E., and Ishii M. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35 (2000) 998-1001
13. Benter I.F., Yousif M.H.M., Anim J.T., Cojocel C., and Diz D.I. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats-treated with l-NAME. Am J Physiol Heart Circ Physiol 290 (2006) H684-H691
14. Benter I.F., Yousif M.H.M., Cojocel C., Al-Maghrebi M., and Diz D.I. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292 (2007) H666-H672
15. Azadzoi K.M., and Saenz de Tejada I. Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 148 (1992) 1587-1591
16. Chang S., Hypolite J.A., Velez M., Changolkar A., Wein A.J., Chacko S., et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol 287 (2004) R950-R960
17. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 (2003) 8258-8263
18. Weber M.A. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. Rev Cardiovasc Med 3 (2002) 183-191
19. Faria-Silva R., Duarte F.V., and Santos R.A.S. Short-term angiotensin(1-7) receptor mas stimulation improves endothelial function in normotensive rats. Hypertension 46 (2005) 948-952
20. Werner M.E., Zvara P., Meredith A.L., Aldrich R.W., and Nelson M.T. Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel. J Physiol 1 (2005) 545-556
21. Lee S.W., and Kang T.M. Effects of nitric oxide on the Ca2+-activated potassium channels in smooth muscle cells of the human corpus cavernosum. Urol Res 29 (2001) 359-365
22. Sampaio W.O., Souza dos Santos R.A., Faria-Silva R., da Mata Machado L.T., Schiffrin E.L., and Touyz R.M. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49 (2007) 185-192
23. Zhi J.-M., Chen R.-F., Wang J., Jiao X.-Y., and Zhao R.-R. Comparative studies of vasodilating effects of angiotensin-(1-7) on the different vessels. Acta Physiolog Sinica 56 (2004) 730-734
24. Tran Y., and Forster C. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol 30 (1997) 676-682
25. Mahon J.M., Carr R.D., Nicol A.K., and Henderson I.W. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens 12 (1994) 1377-1381
26. Porsti I., Bara A., Busse R., and Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 111 (1994) 652-654
27. Brosnihan K.B., Li P., and Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27 (1996) 523-528
28. Paula R.D., Lima C.V., Khosla M.C., and Santos R.A. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26 (1995) 1154-1159
29. Ueda S., Masumori-Maemoto S., Wada A., Ishii M., Brosnihan K.B., and Umemura S. Angiotensin-(1-7) potentiates bradykinin-induced vasodilatation in man. J Hypertens 19 (2001) 2001-2009
30. Sampaio W.O., Santos R.A.S., and Gratton J.P. Angiotensin-(1-7) negatively modulates angiotensin II in human endothelial cells. Hypertension 46 (2005) 820 (abstract)
31. Zhu Z., Zhong J., Zhu S., Liu D., Van Der Giet M., and Tepel M. Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction. J Cardiovasc Pharmacol 40 (2002) 693-700
32. Su Z., Zimpelmann J., and Burns K.D. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69 (2006) 2212-2218
33. Cartledge J.J., Eardley I., and Morrison J.F. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 87 (2001) 394-401
34. Christ G.J., Stone B., and Melman A. Age-dependent alterations in the efficacy of phenylephrine-induced contractions in vascular smooth muscle isolated from the corpus cavernosum of impotent men. Can J Physiol Pharmacol 69 (1991) 909-913
35. Wespes E. Smooth muscle pathology and erectile dysfunction. Int J Impot Res 14 (2002) S17-S21
36. Iyer S.N., Chappell M.C., Averill D.B., Diz D.I., and Ferrario C.M. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31 (1998) 699-705
37. Iyer S.N., Ferrario C.M., and Chappell M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31 (1998) 356-361
38. 1 receptors regulate ACE2 and angiotensin-(1-7) expression in aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289 (2005) H1013-H1019
39. Ha H., and Lee H.B. Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab rep 1 (2001) 282-287
40. Kassab E., McFarlane S.I., and Sowers J.R. Vascular complications in diabetes and their prevention. Vasc Med 6 (2001) 249-255
41. Modinger P.S., Wilcox C.S., and Aslam S. Nitric oxide, oxidative stress and progression of chronic renal failure. Semin Nephrol 24 (2004) 354-365
42. Feldman H.A., Goldstein I., Hatzichristou R.J., Krane R.J., and McKinlay J.B. Impotence and its medical and psychological correlates: results of the Massachusetts male aging study. J Urol 151 (1994) 54-61
43. Burnier M., and Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24 (2006) 11-25
44. Tikellis C., Cooper M.E., and Thomas M.C. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int J Biochem Cell Biol 38 (2005) 737-751
45. Mooradian A.D. Cardiovascular disease in Type 2 diabetes mellitus: current management guidelines. Arch Intern Med 163 (2003) 33-40